{"id":7755,"date":"2022-01-24T03:30:35","date_gmt":"2022-01-24T02:30:35","guid":{"rendered":"http:\/\/www.infokuryr.cz\/n\/?p=7755"},"modified":"2022-01-24T03:34:38","modified_gmt":"2022-01-24T02:34:38","slug":"studie-firmy-pfizer-myty-a-fakta-o-studii-ktera-spustila-celosvetove-ockovani","status":"publish","type":"post","link":"https:\/\/www.infokuryr.cz\/n\/2022\/01\/24\/studie-firmy-pfizer-myty-a-fakta-o-studii-ktera-spustila-celosvetove-ockovani\/","title":{"rendered":"Studie firmy Pfizer \u2013 m\u00fdty a fakta o studii, kter\u00e1 spustila celosv\u011btov\u00e9 o\u010dkov\u00e1n\u00ed"},"content":{"rendered":"<div id=\"fb-root\"><\/div>\n<section class=\"perex\"><strong>N\u00e1sleduj\u00edc\u00ed text a p\u0159ilo\u017een\u00e1 prezentace odhaluje zaml\u010dovan\u00e9 skute\u010dnosti\u00a0ve studii firmy Pfizer\u00a0a z\u00e1va\u017en\u00e1 pochyben\u00ed, kter\u00fdch se dopustily schvalovac\u00ed org\u00e1ny.Hledali jsme pe\u010dliv\u011b d\u016fkazy, kter\u00e9 by vyvr\u00e1tily vyj\u00e1d\u0159en\u00ed kanadsk\u00fdch l\u00e9ka\u0159\u016f, ale na \u017e\u00e1dn\u00e9 jsme nep\u0159i\u0161li, proto jsem se rozhodli text zve\u0159ejnit, jeliko\u017e se jedn\u00e1 o nesm\u00edrn\u011b z\u00e1va\u017en\u00e9 skute\u010dnosti, kter\u00e9 mohou m\u00edt dalekos\u00e1hl\u00e9 d\u016fsledky, na kter\u00e9 mus\u00ed vl\u00e1dy v\u0161ech st\u00e1t\u016f okam\u017eit\u011b reagovat. Pokud by se kanad\u0161t\u00ed l\u00e9ka\u0159i m\u00fdlili, nech\u0165 Pfizer p\u0159edlo\u017e\u00ed d\u016fkazy, \u017ee uveden\u00e9 skute\u010dnosti nejsou pravdiv\u00e9.<\/p>\n<p><\/strong><\/section>\n<section class=\"clanek-obsah\">N\u00e1sleduj\u00edc\u00ed text a p\u0159ilo\u017een\u00e1\u00a0<a href=\"https:\/\/drive.google.com\/file\/d\/1LLKIbs_Jsw71r-ISkS9fRZ9w_nDLP8Hy\/view?usp=sharing\" target=\"_blank\" rel=\"external noopener\">prezentace<\/a>\u00a0(\u010desk\u00fd p\u0159eklad) odhaluj\u00ed zaml\u010dovan\u00e9 skute\u010dnosti a z\u00e1va\u017en\u00e1 pochyben\u00ed ve studii firmy Pfizer, kter\u00fdch se dopustily schvalovac\u00ed org\u00e1ny. Ve sv\u011btle t\u011bchto fakt\u016f se zaveden\u00ed plo\u0161n\u00e9 vakcinace celosv\u011btov\u00e9 populace op\u00edr\u00e1 o velmi vratk\u00e9 z\u00e1klady. V budoucnu se m\u016f\u017ee uk\u00e1zat rozsah i dosah tohoto selh\u00e1n\u00ed medic\u00edny a politik\u016f, ale i v\u0161ech odpov\u011bdn\u00fdch.Od vypuknut\u00ed nemoci covid-19 se odborn\u00e1 ve\u0159ejnost up\u00ednala k\u00a0uveden\u00ed vakc\u00edny na trh.\u00a0 Pro schv\u00e1len\u00ed vakc\u00edny mRNA firmy Pfizer byla kl\u00ed\u010dov\u00e1 studie t\u00e9\u017ee firmy\u00a0<a href=\"https:\/\/www.nejm.org\/doi\/full\/10.1056\/nejmoa2034577\" target=\"_blank\" rel=\"external noopener\">uve\u0159ejn\u011bna<\/a>\u00a0ve v\u011bdeck\u00e9m \u010dasopise\u00a0<i>New England Journal of Medicine<\/i>\u00a0(1). Na z\u00e1klad\u011b t\u00e9to studie bylo pou\u017eit\u00ed vakc\u00edny schv\u00e1leno v\u00a0nouzov\u00e9m re\u017eimu a bylo zah\u00e1jeno plo\u0161n\u00e9 o\u010dkov\u00e1n\u00ed dosp\u011bl\u00fdch. Pozd\u011bji n\u00e1sledovala studie proveden\u00e1 na d\u011btech a o\u010dkov\u00e1n\u00ed bylo roz\u0161\u00ed\u0159eno i na n\u011b.<\/p>\n<p>Vzhledem k\u00a0plo\u0161n\u00e9mu pou\u017eit\u00ed nov\u00e9ho typu vakc\u00edn v\u00a0celosv\u011btov\u00e9m m\u011b\u0159\u00edtku bychom p\u0159edpokl\u00e1dali maxim\u00e1ln\u011b pe\u010dliv\u00e9\u00a0proveden\u00ed studie. Jak ukazuje\u00a0<a href=\"https:\/\/www.canadiancovidcarealliance.org\/media-resources\/the-pfizer-inoculations-for-covid-19-more-harm-than-good-2\/?__cf_chl_f_tk=9Srl.h8Z8CszHIuMto42E0l.DQnWvxznNtkcDn6.Vb4-1642352482-0-gaNycGzNCBE\" target=\"_blank\" rel=\"external noopener\">anal\u00fdza<\/a>\u00a0kanadsk\u00fdch l\u00e9ka\u0159\u016f \u00a0v\u011bdc\u016f z Canadian Covid Care Alliance, bohu\u017eel tomu tak v\u016fbec\u00a0nebylo. Ve studii do\u0161lo k\u00a0dezinterpretaci dat a z\u00e1sadn\u00edm pochyben\u00edm, kter\u00e1 se jev\u00ed jako \u00fa\u010delov\u00e1.<\/p>\n<p>P\u0159edev\u0161\u00edm je t\u0159eba zd\u016fraznit, \u017ee studie netestovala, zda vakcinace br\u00e1n\u00ed \u0161\u00ed\u0159en\u00ed viru, ani se nezam\u011b\u0159ila na to, zda maj\u00ed o\u010dkovan\u00ed ni\u017e\u0161\u00ed \u00famrtnost. Celkov\u00e1 \u00famrtnost (bez ohledu na p\u0159\u00ed\u010dinu) byla v obou skupin\u00e1ch pom\u011brn\u011b srovnateln\u00e1 (ve skupin\u011b o\u010dkovan\u00fdch zem\u0159elo 20 osob, ve skupin\u011b s placebem 14). V\u00fdstupem studie byla pouze PCR pozitivita testu a z\u00e1rove\u0148 klinick\u00e9 projevy infekce (p\u0159i\u010dem\u017e posta\u010doval \u00a0jeden p\u0159\u00edznak). To je z\u00a0hlediska argumentace pro zaveden\u00ed plo\u0161n\u00e9 vakcinace nedostate\u010dn\u00e9. Je zde ale rovn\u011b\u017e cel\u00e1 \u0159ada dal\u0161\u00edch z\u00e1va\u017en\u00fdch nedostatk\u016f.<\/p>\n<h2>A. Zaml\u010dov\u00e1n\u00ed probl\u00e9m\u016f a ne\u017e\u00e1douc\u00edch \u00fa\u010dink\u016f:<\/h2>\n<p><i>1.\u00a0\u00a0Protokol klinick\u00e9 studie byl opakovan\u011b a velmi z\u00e1va\u017en\u011b poru\u0161en v\u00a0t\u011bchto bodech<\/i><\/p>\n<ul>\n<li>Nedovolen\u00e1 manipulace s\u00a0odebran\u00fdmi vzorky, falzifikace dat.<\/li>\n<li>Nedostate\u010dn\u00e9 sledov\u00e1n\u00ed pacient\u016f a v\u010detn\u011b zaml\u010den\u00ed hl\u00e1\u0161en\u00fdch vedlej\u0161\u00edch p\u0159\u00edznak\u016f.<\/li>\n<li>Nedodr\u017een\u00e9 zaslepen\u00ed obou skupin (v\u00fdzkumn\u00edci v\u011bd\u011bli, kte\u0159\u00ed pacienti dost\u00e1vaj\u00ed placebo).<\/li>\n<\/ul>\n<p>Tyto nedostatky byly\u00a0<a href=\"https:\/\/www.bmj.com\/content\/375\/bmj.n2635\" target=\"_blank\" rel=\"external noopener\">publikov\u00e1ny<\/a>\u00a0v \u00a0presti\u017en\u00edm v\u011bdeck\u00e9m \u010dasopisu British Medical Journal (BMJ) 2. \u0159\u00edjna 2021 (2), byly dolo\u017eeny p\u00edsemn\u011b a sv\u011bdectv\u00edm pan\u00ed Brooke Jackson, oblastn\u00ed \u0159editelky firmy Ventavia, kter\u00e1 pracovala pro Pfizer v r\u00e1mci t\u00e9to studie a potvrzeny jej\u00edmi zam\u011bstnanci.\u00a0 N\u00e1sledn\u011b byly nedostatky hl\u00e1\u0161eny na dozoruj\u00edc\u00ed Food and Drug Administration (FDA). Reakc\u00ed byla v\u00fdpov\u011b\u010f pan\u00ed B. Jackson, FDA kontrolu neprovedla a v\u00a0\u017e\u00e1dosti o schv\u00e1len\u00ed vakc\u00edny Pfizer ve\u0161ker\u00e9 probl\u00e9my zaml\u010del.<\/p>\n<p><i>2.\u00a0Nedostate\u010dn\u00e9 sledov\u00e1n\u00ed ne\u017e\u00e1douc\u00edch \u00fa\u010dink\u016f po uveden\u00ed vakc\u00edny na trh<\/i><\/p>\n<p>Aktivn\u00ed sledov\u00e1n\u00ed ne\u017e\u00e1douc\u00edch \u00fa\u010dink\u016f (tzn. povinnost ne\u017e\u00e1douc\u00ed \u00fa\u010dinky hl\u00e1sit) trvala pouze 2,5 m\u011bs\u00edce. B\u011bhem t\u00e9to doby zaznamenal \u00a0Pfizer p\u0159es 1 200 \u00famrt\u00ed a p\u0159es 25 000 ne\u017e\u00e1douc\u00edch \u00fa\u010dink\u016f postihuj\u00edc\u00edch nervov\u00fd syst\u00e9m. Po t\u00e9to dob\u011b n\u00e1hle v\u00fdskyt ne\u017e\u00e1douc\u00edch \u00fa\u010dink\u016f poklesl. Pro\u010d?\u00a0 Proto\u017ee po 2,5 m\u011bs\u00edc\u00edch ji\u017e byly ne\u017e\u00e1douc\u00ed \u00fa\u010dinky sledov\u00e1ny pouze pasivn\u011b \u2013 co\u017e plat\u00ed i nad\u00e1le, jak u dosp\u011bl\u00fdch, tak u d\u011bt\u00ed. V r\u00e1mci pasivn\u00edch syst\u00e9m\u016f sledov\u00e1n\u00ed (VAERS v USA, Yellow Card v Evrop\u011b) je nahl\u00e1\u0161eno pouh\u00fdch 1-10% ne\u017e\u00e1douc\u00edch \u00fa\u010dink\u016f z jejich skute\u010dn\u00e9ho po\u010dtu. I tak ale po\u010det nahl\u00e1\u0161en\u00fdch ne\u017e\u00e1douc\u00edch \u00fa\u010dink\u016f mRNA vakc\u00edn v\u00fdrazn\u011b p\u0159evy\u0161uje historick\u00e9 hodnoty hl\u00e1\u0161en\u00fdch ne\u017e\u00e1douc\u00edch \u00fa\u010dink\u016f po pou\u017eit\u00ed jin\u00fdch vakc\u00edn \u010di l\u00e9\u010div.<\/p>\n<p><i>3.\u00a0Nedostate\u010dn\u00fd monitoring bezpe\u010dnosti<\/i><\/p>\n<p>Pfizer neza\u0159adil do protokolu studie sledov\u00e1n\u00ed n\u011bkter\u00fdch laboratorn\u00edch ukazatel\u016f, \u00a0kter\u00e9 by mohly detekovat \u010dasn\u00e9 varovn\u00e9 sign\u00e1ly dlouhodob\u00fdch rizik.\u00a0 Jedn\u00e1 se o hladiny l\u00e1tek ukazuj\u00edc\u00edch m\u00edru po\u0161kozen\u00ed srde\u010dn\u00edho svalu (nap\u0159. troponin), n\u00e1r\u016fstu z\u00e1n\u011btu v t\u011ble (C-reaktivn\u00ed protein), zv\u00fd\u0161en\u00ed rizika autoimunitn\u00edch poruch, Alzheimerovy choroby a dal\u0161\u00edch rizik.\u00a0 D\u016fsledky t\u011bchto sign\u00e1l\u016f se mohou projevit za n\u011bkolik m\u011bs\u00edc\u016f \u010di let (nap\u0159\u00edklad \u010dasn\u00e9 zn\u00e1mky z\u00e1n\u011btu srde\u010dn\u00edho svalu mohou upozornit na vznik srde\u010dn\u00edho selh\u00e1n\u00ed v budoucnu). Sledov\u00e1n\u00ed bezpe\u010dnosti \u00a0tedy prob\u00edhalo velmi povrchn\u011b. To je u nov\u00e9ho typu vakc\u00edny, kde je na m\u00edst\u011b vysok\u00e1 m\u00edra p\u0159edb\u011b\u017en\u00e9 opatrnosti, alarmuj\u00edc\u00ed.<\/p>\n<p><i>4.\u00a0Zaml\u010dov\u00e1n\u00ed ne\u017e\u00e1douc\u00edch \u00fa\u010dink\u016f<\/i><\/p>\n<p>Ve studii proveden\u00e9 na adolescentech (12-15 let) byla vakc\u00edna pod\u00e1na pouh\u00fdm 1005 osob\u00e1m. Tento vzorek je tak mal\u00fd, \u017ee nen\u00ed schopen spolehliv\u011b zachytit dokonce ani \u010dast\u00e9 ne\u017e\u00e1douc\u00ed \u00fa\u010dinky (nap\u0159. s frekvenc\u00ed 1:800). K z\u00e1va\u017en\u00fdm komplikac\u00edm v t\u00e9to studii v\u0161ak do\u0161lo, ale Pfizer je zaml\u010del. Konkr\u00e9tn\u011b jde o p\u0159\u00edpad dvan\u00e1ctilet\u00e9 Maddie de Garray, kter\u00e1 byla do 24 hodin po druh\u00e9 d\u00e1vce vakc\u00edny hospitalizov\u00e1na s poruchou inervace \u017ealudku, zvracen\u00edm a s v\u00fdrazn\u00fdmi poruchami nervov\u00e9ho syst\u00e9mu v\u010detn\u011b k\u0159e\u010d\u00ed. Stav se postupn\u011b zhor\u0161il, rozvinula se u n\u00ed inkontinence, ztratila citlivost od pasu dol\u016f a nen\u00ed schopna polykat potravu. Maddie je nyn\u00ed upout\u00e1na na invalidn\u00ed voz\u00edk a je vy\u017eivov\u00e1na sondou do \u017ealudku. Invalidizace t\u00e9to doposud zcela zdrav\u00e9 d\u00edvky je ve zpr\u00e1v\u011b o ne\u017e\u00e1douc\u00edch \u00fa\u010dinc\u00edch Pfizerem pops\u00e1na jako \u201efunk\u010dn\u00ed bolest b\u0159icha\u201c, stav pacientky nereflektoval ani Pfizer ani FDA ani Centers for Disease Control and Prevention (CDC). FDA sl\u00edbila pro\u0161et\u0159en\u00ed a\u017e po medializaci cel\u00e9ho p\u0159\u00edpadu.<\/p>\n<p><i>5.\u00a0Bagatelizace myokarditid u adolescent\u016f<\/i><\/p>\n<p>Mezi \u00a0ne\u017e\u00e1douc\u00edmi \u00fa\u010dinky vakc\u00edny Pfizer s\u00e1m uv\u00e1d\u00ed zv\u00fd\u0161en\u00e9 riziko z\u00e1n\u011btu srde\u010dn\u00edho svalu (myokarditida) v\u00a0populaci adolescent\u016f.\u00a0 D\u00e1le Pfizer odhaduje, \u017ee n\u011bkter\u00e9 p\u0159\u00edpady myokarditid skon\u010d\u00ed v\u00a0nemocnici, v\u0161echny d\u011bti se v\u0161ak zotav\u00ed a \u017e\u00e1dn\u00e9 nezem\u0159e. Tento p\u0159edpoklad je spekulativn\u00ed, a i kdyby platil z kr\u00e1tkodob\u00e9ho hlediska, dlouhodob\u00fd v\u00fdvoj je velmi nejist\u00fd. Po prod\u011blan\u00e9 myokarditid\u011b toti\u017e nez\u0159\u00eddka doch\u00e1z\u00ed k rozvoji t\u011b\u017ek\u00e9ho srde\u010dn\u00edho selh\u00e1n\u00ed, kter\u00e9 \u010dasto kon\u010d\u00ed smrt\u00ed.<\/p>\n<p>Jedn\u00e1 se tedy skute\u010dn\u011b o lehkou, nez\u00e1va\u017enou komplikaci? Jak\u00e1 je p\u0159\u00ed\u010dina medi\u00e1ln\u011b zmi\u0148ovan\u00fdch ne\u010dekan\u00fdch kolaps\u016f sportovc\u016f \u010di n\u00e1hl\u00fdch \u00famrt\u00ed mlad\u00fdch lid\u00ed v obdob\u00ed po zah\u00e1jen\u00ed vakcina\u010dn\u00ed kampan\u011b?<\/p>\n<h2>B.\u00a0Nedostatky v\u00a0protokolu studie<\/h2>\n<p>Pokud se jedn\u00e1 o zcela nov\u00fd typ l\u00e9ku \u010di vakc\u00edny, m\u011bly by b\u00fdt s\u00a0ve\u0161kerou p\u0159edb\u011b\u017enou opatrnost\u00ed dodr\u017eeny platn\u00e9 standardy a nem\u011bly by b\u00fdt vynech\u00e1ny kl\u00ed\u010dov\u00e9 f\u00e1ze v\u00fdzkumu. Pokud c\u00edl\u00edme na rizikovou populaci senior\u016f a osob s chronick\u00fdmi chorobami, vakc\u00edna by m\u011bla b\u00fdt testov\u00e1na pr\u00e1v\u011b na t\u00e9to skupin\u011b pacient\u016f.<\/p>\n<p>Bylo tomu tak skute\u010dn\u011b? Nebylo.<\/p>\n<ol>\n<li>D\u00e9lka testov\u00e1n\u00ed vakc\u00edn ve studi\u00edch byla bezprecedentn\u011b zkr\u00e1cena, a to v\u010detn\u011b vynech\u00e1n\u00ed zkou\u0161ek na zv\u00ed\u0159atech.<\/li>\n<li>P\u0159i za\u0159azen\u00ed do studie nebyl zkouman\u00fdm osob\u00e1m prov\u00e1d\u011bn PCR test na Covid-19, aby se zjistilo, zda nejsou infikovan\u00ed. Rozhodnut\u00ed, zda jsou tyto osoby infikovan\u00e9, bylo subjektivn\u00ed, bez jasn\u011b dan\u00fdch krit\u00e9ri\u00ed.<\/li>\n<li>P\u0159i za\u0159azen\u00ed osob do studie nebylo zji\u0161\u0165ov\u00e1no, zda v minulosti prod\u011blaly Covid-19, by\u0165 tato skute\u010dnost z\u00e1sadn\u011b ovliv\u0148uje \u00fa\u010dinnost i ne\u017e\u00e1douc\u00ed \u00fa\u010dinky vakcinace.<\/li>\n<li>Do studie byla za\u0159azena pouh\u00e1 4 % osob ve v\u011bku nad 75 let.\u00a0 V\u011bt\u0161ina osob ve studii (58 %) byla mlad\u0161\u00ed ne\u017e 55 let, tedy z\u00a0hlediska t\u011b\u017ek\u00e9ho pr\u016fb\u011bhu Covid-19 nerizikov\u00e1. P\u0159itom stanoven\u00ed p\u0159\u00ednos\u016f vakcinace oproti ne\u017e\u00e1douc\u00edm \u00fa\u010dink\u016fm je kl\u00ed\u010dov\u00e9 pr\u00e1v\u011b pro star\u0161\u00ed a k\u0159ehk\u00e9 \u010di polymorbidn\u00ed pacienty, kte\u0159\u00ed jsou rizikov\u00ed z\u00a0hlediska t\u011b\u017ek\u00e9ho pr\u016fb\u011bhu nemoci.<\/li>\n<li>Do studie byli za\u0159azeni p\u0159edev\u0161\u00edm zdrav\u00ed lid\u00e9 (pouze 21 % testovan\u00fdch trp\u011blo n\u011bjakou dal\u0161\u00ed chorobou).\u00a0 P\u0159itom \u00a095 % lid\u00ed zem\u0159el\u00fdch na \u00a0Covid-19 \u00a0trp\u011blo nejm\u00e9n\u011b jednou chronickou chorobou (v pr\u016fm\u011bru v\u0161ak \u010dty\u0159mi chronick\u00fdmi onemocn\u011bn\u00edmi!).<\/li>\n<li>Riziko t\u011b\u017ek\u00e9ho pr\u016fb\u011bhu \u00a0Covid-19 \u00a0je v\u00fdrazn\u011b vy\u0161\u0161\u00ed u ob\u00e9zn\u00edch pacient\u016f. P\u0159esto bylo do studie za\u0159azeno pouze 35 % ob\u00e9zn\u00edch osob (BMI &gt; 30).<\/li>\n<li>\u00dadajn\u011b vysok\u00e1 \u00fa\u010dinnost vakc\u00edny byla odvozena od toho, \u017ee ve vakcinovan\u00e9 skupin\u011b bylo 8 osob testov\u00e1no pozitivn\u011b na Covid-19, zat\u00edmco ve skupin\u011b s placebem 162 osob (z celkem 43 548 zkouman\u00fdch osob). Pokud budeme hodnotit klinickou \u00fa\u010dinnost vakc\u00edny \u2013 definovanou na z\u00e1klad\u011b klinick\u00fdch p\u0159\u00edznak\u016f (1594 osob ve skupin\u011b vakcinovan\u00fdch a 1816 osob ve skupin\u011b s placebem m\u011blo p\u0159\u00edznaky Covid-19), dojdeme ke klinick\u00e9 \u00fa\u010dinnosti vakc\u00edny pouh\u00fdch 19 %. P\u0159itom dle WHO je pro schv\u00e1len\u00ed vakc\u00edn nutn\u00e9 p\u0159ekonat hranici 50 %.<\/li>\n<li>Pfizer \u00fa\u010delov\u011b uv\u00e1d\u011bl vysokou relativn\u00ed \u00fa\u010dinnost vakc\u00edny 95 %. Tato interpretace je ov\u0161em zav\u00e1d\u011bj\u00edc\u00ed, nebo\u0165 se jedn\u00e1 o sn\u00ed\u017een\u00ed relativn\u00edho rizika infekce pro neo\u010dkovan\u00e9. Sn\u00ed\u017een\u00ed absolutn\u00edho rizika \u2013 dopad vakcinace na popula\u010dn\u00ed \u00farovni je pouze 0.84 %. To znamen\u00e1, \u017ee pouze necel\u00e9 jedno procento osob ve studii neonemocn\u011blo d\u00edky tomu, \u017ee byly vakcinov\u00e1ny. \u00da\u010delov\u00e1 argumentace \u00a0\u00fa\u010dinnost\u00ed vakc\u00edny pouze na z\u00e1klad\u011b sn\u00ed\u017een\u00ed relativn\u00edho rizika je p\u0159i zaml\u010den\u00ed hodnoty absolutn\u00edho rizika manipulativn\u00ed.\u00a0 Ob\u011b hodnoty je v\u017edy t\u0159eba uv\u00e1d\u011bt spole\u010dn\u011b.<\/li>\n<\/ol>\n<h2>Z\u00e1v\u011br<\/h2>\n<p>Je z\u0159ejm\u00e9, \u017ee klinick\u00e9 studie firmy Pfizer, na jejich\u017e z\u00e1klad\u011b bylo zah\u00e1jeno celosv\u011btov\u00e9 plo\u0161n\u00e9 o\u010dkov\u00e1n\u00ed populace, maj\u00ed p\u0159\u00edli\u0161 mnoho nedostatk\u016f. Nam\u00edsto jejich vysv\u011btlen\u00ed a dopln\u011bn\u00ed informac\u00ed jsme sv\u011bdky n\u00e1tlaku na vakcinaci a revakcinaci v\u00a0situaci, kdy nen\u00ed zaru\u010dena bezpe\u010dnost vakc\u00edn a firmy nenesou \u017e\u00e1dnou odpov\u011bdnost za p\u0159\u00edpadn\u00e9 vedlej\u0161\u00ed \u00fa\u010dinky. To je alarmuj\u00edc\u00ed, proto\u017ee v ned\u00e1vn\u00e9 minulosti byl Pfizer (i dal\u0161\u00ed farmaceutick\u00e9 firmy) usv\u011bd\u010den a odsouzen kv\u016fli korupci a zaml\u010dov\u00e1n\u00ed dat vedouc\u00edm k po\u0161kozov\u00e1n\u00ed a \u00famrt\u00edm pacient\u016f.<\/p>\n<p>V\u00a0situaci, kdy se jedn\u00e1 o z\u00e1le\u017eitost glob\u00e1ln\u00edho v\u00fdznamu, je nezbytn\u00e1 maxim\u00e1ln\u00ed obez\u0159etnost regula\u010dn\u00edch org\u00e1n\u016f (FDA), proto\u017ee p\u0159\u00edpadn\u00e9 nap\u00e1chan\u00e9 \u0161kody mohou b\u00fdt nedoz\u00edrn\u00e9.\u00a0 Vl\u00e1dy jednotliv\u00fdch zem\u00ed by m\u011bly postupovat v\u00a0souladu s platn\u00fdmi a osv\u011bd\u010den\u00fdmi medic\u00ednsk\u00fdmi principy v\u00a0z\u00e1jmu sv\u00fdch ob\u010dan\u016f, nikoli ve slep\u00e9 d\u016fv\u011b\u0159e v doporu\u010den\u00ed nadn\u00e1rodn\u00edch farmaceutick\u00fdch korporac\u00ed.<\/p>\n<p><b>MUDr. Emil Berta, PhD.<\/b><\/p>\n<h2>Odkazy:<\/h2>\n<ol>\n<li>Polack FP et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. 2020 Dec 31;383(27):2603-2615. doi: 10.1056\/NEJMoa2034577. Epub 2020 Dec 10. PMID: 33301246; PMCID: PMC7745181.<\/li>\n<li>Thacker P D. Covid-19: Researcher blows the whistle on data integrity issues in Pfizer\u2019s vaccine trial BMJ 2021; 375 :n2635 doi:10.1136\/bmj.n2635<\/li>\n<\/ol>\n<p><em>\u010cl\u00e1nek vy\u0161el 10.1.2022 na str\u00e1nce Sdru\u017een\u00ed mikrobiolog\u016f, imunolog\u016f a statistik\u016f SMIS.<\/em><\/p>\n<p>&nbsp;<\/p>\n<\/section>\n","protected":false},"excerpt":{"rendered":"<p>N\u00e1sleduj\u00edc\u00ed text a p\u0159ilo\u017een\u00e1 prezentace odhaluje zaml\u010dovan\u00e9 skute\u010dnosti\u00a0ve studii firmy Pfizer\u00a0a z\u00e1va\u017en\u00e1 pochyben\u00ed, kter\u00fdch se&#8230;<\/p>\n","protected":false},"author":2,"featured_media":5887,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":[],"categories":[7],"tags":[1042,315,497,46],"_links":{"self":[{"href":"https:\/\/www.infokuryr.cz\/n\/wp-json\/wp\/v2\/posts\/7755"}],"collection":[{"href":"https:\/\/www.infokuryr.cz\/n\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.infokuryr.cz\/n\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.infokuryr.cz\/n\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.infokuryr.cz\/n\/wp-json\/wp\/v2\/comments?post=7755"}],"version-history":[{"count":0,"href":"https:\/\/www.infokuryr.cz\/n\/wp-json\/wp\/v2\/posts\/7755\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.infokuryr.cz\/n\/wp-json\/wp\/v2\/media\/5887"}],"wp:attachment":[{"href":"https:\/\/www.infokuryr.cz\/n\/wp-json\/wp\/v2\/media?parent=7755"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.infokuryr.cz\/n\/wp-json\/wp\/v2\/categories?post=7755"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.infokuryr.cz\/n\/wp-json\/wp\/v2\/tags?post=7755"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}